Clinical trials: RhA - Rheumatoid Arthritis
Osteoarthritis, Rheumatoid Arthritis
Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)
This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Gout
- Trial name
- NCT01685424
- Testing
- Etoricoxib
- Volunteers
- 79,189 people
- Sponsor
- Organon and Co
Rheumatoid Arthritis (RA)
Treatment With Auricular Vagus Nerve Stimulation in Rheumatoid Arthritis - the TRAVAGA Study
Purpose and aim The overall aim is to investigate efficacy and safety of a newly developed non-invasive auricular investigational device that electrically stimulates the auricular branch of the vagus nerve to activate the…
- Trial name
- TRAVAGA (NCT06779123)
- Testing
- Transauricular vagus nerve stimulation., transauricular vagus nerve non-stimulation
- Where
- 6 sites in Sweden
- Volunteers
- 128 people
- Sponsor
- taVNS AB
Rheumatoid Arthritis
A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s…
- Trial name
- NCT00195403
- Testing
- Etanercept
- Where
- 4 sites in South Korea
- Volunteers
- 1,014 people
- Sponsor
- Pfizer
Arthritis of Temporomandibular Joint, Temporomandibular Arthritis
Treatment of Temporomandibular Joint Osteoarthritis by Viscosupplement. Satisfaction Predictive Factors
The arthritis of temporomandibular joint is the most frequent degenerative disease of the jaw joint. Several clinical studies recommend the recourse to the viscosupplement because of its efficiency in the long term.
- Trial name
- ARTEMIS (NCT03627429)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Labrha
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo in combination with traditional Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy in…
- Trial name
- NCT00106574
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 146 sites in United States, Argentina and 17 more
- Volunteers
- 1,220 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a…
- Trial name
- NCT01089023
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in Bahrain, Iran and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
- Trial name
- NCT01274182
- Testing
- GP2013, MabThera, Rituxan
- Where
- 57 sites in United States, Argentina and 12 more
- Volunteers
- 312 people
- Sponsor
- Sandoz
Rheumatoid Arthritis
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
This single arm study will assess the safety of MabThera plus methotrexate in patients with rheumatoid arthritis who have had a lack of response to 1-5 DMARDs or biological agents.
- Trial name
- NCT00502996
- Testing
- Methotrexate, rituximab [MabThera/Rituxan]
- Where
- 49 sites in Argentina, Brazil and 8 more
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Psoriasis, Rheumatoid Arthritis
BE Study in Patients - Methotrexate Tablets
To characterize the pharmacokinetic profile of the Test product - Methotrexate Tablets USP, 2.5 mg of Amneal Pharmaceuticals, compared to that of the corresponding Reference product - Methotrexate Tablets USP 2.5 mg manufactured…
- Trial name
- NCT02940561
- Testing
- Methotrexate - Amneal, Methotrexate - DAVA
- Where
- 3 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Rheumatoid Arthritis
Long-term Experience With Abatacept SC in Routine Clinical Practice
The purpose of this study is to estimate the retention rate of Abatacept SC over 24 months in routine clinical practice, in rheumatoid arthritis patients, in each country involved in the study.
- Trial name
- ASCORE (NCT02090556)
- Where
- 12 sites in Australia, Austria and 9 more
- Volunteers
- 2,954 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
This is a Phase 1 single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06835375 in subjects with seropositive SLE or RA.
- Trial name
- NCT03334851
- Testing
- PF-06835375
- Where
- 17 sites in United States
- Volunteers
- 74 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies.
- Trial name
- NCT00462345
- Testing
- rituximab, Methotrexate, Corticosteroid or NSAID
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to Humira® in subjects with moderate to severe RA…
- Trial name
- NCT02167139
- Testing
- Humira (adalimumab), SB5 (proposed biosimilar to adalimumab)
- Where
- 2 sites in Lithuania, Poland
- Volunteers
- 544 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis
This primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic properties of multiple ascending doses of ATN-103 administered subcutaneously (below the skin) to Japanese subjects with active…
- Trial name
- NCT01007175
- Testing
- ATN-103 10 mg q4wks, ATN-103 30 mg q4wks, ATN-103 80 mg q4wks
- Where
- 15 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Ablynx, a Sanofi company
Arthritis, Rheumatoid, Inflammation
A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose
SB-681323 inhibits the action of an enzyme which is known to contribute to the inflammation seen in such conditions as Chronic Obstructive Pulmonary Disease and Rheumatoid Arthritis.
- Trial name
- NCT00439881
- Testing
- SB-681323
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
CT-P13 (Infliximab) is a monoclonal antibody currently being developed by CELLTRION, Inc. This open-label, single-arm, multicenter, multiple single dose intravenous (IV) infusion, efficacy, and safety extension study of the Phase…
- Trial name
- NCT01571219
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 302 people
- Sponsor
- Celltrion
Coxarthrosis; Primary, Coxarthrosis; Post-Traumatic
Cemented TrendHip® - Multicenter PMCF Study on Total Indications
This Post Market Clinical Follow-Up (PMCF) study to evaluate the performance and safety of the cemented TrendHip® stem in a prospective follow-up study with patients who underwent a hip arthroplasty with the investigational…
- Conditions
- Coxarthrosis; Primary, Coxarthrosis; Post-Traumatic, Necrosis, Femur Head, Rheumatoid Arthritis
- Trial name
- TRESTI (NCT04943328)
- Testing
- Total Hip Arthroplasty
- Where
- 4 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Aesculap AG
Rheumatoid Arthritis
Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)
The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with disease-modifying antirheumatic drug.
- Trial name
- AMOLED (NCT02005757)
- Testing
- Bredinin tablet 150mg, Bredinin tablet 50mg
- Where
- 7 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Osteoarthritis, Rheumatoid Arthritis
6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
This study tested the safety, tolerability and efficacy of lumiracoxib - a COX-2 inhibitor- in patients with primary knee osteoarthritis or rheumatoid arthritis.
- Trial name
- NCT00170872
- Testing
- Lumiracoxib
- Volunteers
- 135 people
- Sponsor
- Novartis
Rheumatoid Arthritis
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX).
- Trial name
- Dose Flex II (NCT00753454)
- Testing
- Certolizumab pegol
- Where
- 40 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- UCB Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.